27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Atreca Inc (NASDAQ:BCEL) stock is hovering at a 52-week low after it announced initial data from the dose-escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Twenty-six participants were dosed. Eight of the 20 participants (40%) evaluable experienced stable disease (SD), including four with tumor reduction observed.
- The remaining 12 participants had progressive disease.
- Disease control observed in the study was associated with target expression.
- Three of six (50%) of participants with evaluable response assessments and baseline tumor H-scores over 50 achieved SD, compared with 1 of 9 (11%) evaluable participants with an H-score below 50.
- Expansion of peripheral blood CD8+ T cells was observed on day eight following dosing with ATRC-101.
- The Company will report additional data from monotherapy dose-expansion cohorts in the Phase 1b trial and combination cohorts with pembrolizumab in 2022.
- Price Action: BCEL shares are down 34.9% at $5.35 during the market session on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.